Abstract
Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 217-220 |
| Number of pages | 4 |
| Journal | Cancer Immunology and Immunotherapy |
| Volume | 5 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 1979 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Immunology
- Cancer Research
Cite this
Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine. / Pardridge, Daria H.; Sparks, F. C.; Goodnight Jr, James E; Spears, Irene K.; Morton, D. L.
In: Cancer Immunology and Immunotherapy, Vol. 5, No. 4, 02.1979, p. 217-220.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine
AU - Pardridge, Daria H.
AU - Sparks, F. C.
AU - Goodnight Jr, James E
AU - Spears, Irene K.
AU - Morton, D. L.
PY - 1979/2
Y1 - 1979/2
N2 - Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.
AB - Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.
UR - http://www.scopus.com/inward/record.url?scp=0018648017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018648017&partnerID=8YFLogxK
U2 - 10.1007/BF00200143
DO - 10.1007/BF00200143
M3 - Article
AN - SCOPUS:0018648017
VL - 5
SP - 217
EP - 220
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
SN - 0340-7004
IS - 4
ER -